Olympus expands oncology portfolio with USD 270 million acquisition of BioProtect
Olympus Corporation has entered a definitive agreement to acquire BioProtect Ltd. for $270 million. This strategic move secures an innovative biodegradable balloon spacer technology used in radiation therapy for prostate cancer, reinforcing Olympus’ specialized urological and gastrointestinal medical device offerings.